Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07223398 · ClinicalTrials.gov registry record · NA

Shared Decision Making to Treat Or Prevent (STOP) HIV in Justice Populations (R33)

A NA study of Substance Use Disorders, sponsored by Yale University.

Recruiting
Registry status
NA
Development phase
400
Enrollment target
4
Study locations

NCT07223398: Recruiting NA study of Substance Use Disorders, sponsored by Yale University.

NCT07223398 is a NA study of Substance Use Disorders that is actively recruiting participants, run by Yale University. The registered enrollment target is 400 participants, below the 496-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (19% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07223398, a NA study of Substance Use Disorders, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
NA
Development phase
400 participants
Enrollment target
4
Study locations

Study Summary

This study seeks to compare the effectiveness of two Patient Navigation models of care to evaluate the proportion who initiate PrEP/ART and substance use/substance use disorder (SU/SUD) treatment. A standardized Patient Navigation (PN) arm will be compared with a shared decision-making model in the form of Patient Choice (PC) through the offer of a menu of existing community-based health service delivery options. This design will offer providers, correctional and public health authorities, payers and policy makers' timely and relevant data to assess the effectiveness of Patient Navigation and Patient Choice models of care as potentially useful re-entry and relapse prevention treatment options.

Primary Outcome

Percentage of participants not living with HIV who initiate or re-initiate PrEP within the 6-month intervention period by self report

Conditions Studied

Interventions

  • BEHAVIORAL Standard PN
  • BEHAVIORAL Patient Choice

Study Locations (4)

Texas

  • University of Texas Southwestern Medical Center (UTSW) - Dallas
  • Texas Christian University's (TCU) School of Medicine - Fort Worth

Connecticut

  • Yale School of Medicine - New Haven

Kentucky

  • College of Medicine at the University of Kentucky - Lexington

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2025-11-24
Est. Completion 2028-06
Phase NA
Yale University

1,492 total trials

What NCT07223398 shows while recruiting

NCT07223398 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 496-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (19% lower).

The record links to 1 condition, with Substance Use Disorders appearing as the primary indexed condition, and to 2 interventions - of which Standard PN is the first listed.

NCT07223398 reports a single indexed study location in Texas, Connecticut, Kentucky.

Frequently Asked Questions

What is clinical trial NCT07223398 about?

NCT07223398 is a clinical study titled "Shared Decision Making to Treat Or Prevent (STOP) HIV in Justice Populations (R33)". This study seeks to compare the effectiveness of two Patient Navigation models of care to evaluate the proportion who initiate PrEP/ART and substance use/substance use disorder (SU/SUD) treatment. A standardized Patient Navigation (PN) arm will be compared with a shared decision-making model in the ...

What is the current status of trial NCT07223398?

This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2025-11-24. Estimated completion is 2028-06.

What conditions does trial NCT07223398 study?

This clinical trial studies the following conditions: Substance Use Disorders.

What interventions are being tested in trial NCT07223398?

The interventions under investigation include: Standard PN (BEHAVIORAL), Patient Choice (BEHAVIORAL).

Who is sponsoring clinical trial NCT07223398?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07223398 being conducted?

This trial has 4 study locations across Connecticut, Kentucky, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Substance Use Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07223398's enrollment target sits among peer trials

400 11th of 93 higher than 81 of 93 other Substance Use Disorders trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Substance Use Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07223398, the US trial registry maintained by the National Library of Medicine. NCT07223398 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.